Moneycontrol PRO
Register now: : Join us for & Property Share CRE EDGE Wealth Generation Through Commercial Real Estate webinar on Thursday, 30th March 2023 | 5 pm onwards.
you are here: HomeNewsIndia

Cipla gets DCGI nod for import of Moderna COVID-19 vaccine: Reports

The clearance came shortly after Cipla moved an application before India's apex drug regulatory body, seeking early approval for the import of Moderna vaccine for restricted emergency use.

June 29, 2021 / 04:09 PM IST
Representative image (Source: Reuters)

Representative image (Source: Reuters)

Pharmaceutical firm Cipla has received regulatory nod from Drug Controller General of India (DCGI) to import the COVID-19 vaccine developed by US-based biotechnology company Moderna Inc, reports said on June 29.

According to news agency ANI, an official announcement from the government is expected shortly.

Earlier on June 29, Cipla sources confirmed to CNBC TV-18 that an application has been filed with India's apex drug regulatory body, seeking the permission to import the Moderna jabs for restricted emergency use.

"The company is seeking clarity and guidance on factors such as pricing, quantity and indemnity clause," the sources told the news channel.

Moderna, similar to the anti-COVID-19 jab co-developed by US pharmaceutical giant Pfizer, is an mRNA vaccine. It is based on a two-dose regimen, with both the shots to be administered at a gap of 28 days. The vaccine has demonstrated an efficacy of 90 percent.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Track this LIVE blog for latest updates on coronavirus pandemic

The import of Moderna vaccine is expected to boost the government's drive to inoculate all adults by December 31, 2021. The Centre is also in talks with Pfizer over the import of its jabs.

Pfizer CEO Albert Bourla said on June 22 that the company is in the "final stages" of talks with India to export its vaccine. The regulatory approval may be granted soon, he suggested.

Reports had earlier suggested that indemnification was a major point of contention in the talks for import of vaccines between the government and the foreign manufacturers.

Notably, Moderna and Pfizer had earlier declined the request of Indian state governments who had sought to import their jabs. Both the companies underlined that they would deal only with the federal authority - which is the Government of India.

Moneycontrol News
first published: Jun 29, 2021 03:34 pm